PDUFA Calendar 2026: Complete FDA Drug Approval Dates for Investors

Every biotech investor needs to know when the FDA is making decisions. PDUFA dates are the single most impactful catalyst events in the pharmaceutical sector — binary outcomes that can move stock prices 30-100% in either direction within minutes. Missing a PDUFA date for a stock you hold is inexcusable, and failing to know about upcoming dates for stocks on your watchlist means missing some of the highest-probability setups in the market.

This guide covers the complete landscape of FDA decision dates for 2026, explains the PDUFA system, and provides a strategic framework for trading around these catalysts. For a live, continuously updated calendar, visit the BiotechSigns PDUFA Calendar, which scores each upcoming catalyst for approval probability and market impact.

Understanding PDUFA Dates

What PDUFA Is

The Prescription Drug User Fee Act was first enacted in 1992 and reauthorized every five years since. Under PDUFA, pharmaceutical companies pay fees to the FDA to fund the drug review process, and in exchange, the FDA commits to specific review timelines. These timeline commitments create the PDUFA dates that drive biotech stock prices.

There are two review pathways with different timelines:

• Standard Review: 10-month review period from NDA/BLA acceptance. The PDUFA date is set at the end of this 10-month window. Most drugs go through standard review.
• Priority Review: 6-month review period. Granted to drugs that offer significant improvements over existing treatments for serious conditions. Priority Review is a positive signal — it means the FDA sees potential in the drug and wants to get it to patients faster.

What Happens on (or Before) a PDUFA Date

The FDA has three options at PDUFA:

• Approval: The drug is approved for marketing. The approval letter specifies the approved indication(s), dosing, and any post-marketing requirements (REMS, Phase 4 studies). Stock impact: typically +20-80% for small/mid-cap biotechs, +5-15% for large pharma.
• Complete Response Letter (CRL): The FDA identifies deficiencies that must be addressed before approval. CRLs range from minor (labeling issues, manufacturing changes) to major (additional clinical data needed). Stock impact: typically -40-80% for small/mid-cap, -10-25% for large pharma.
• Extension: The FDA can extend the review period by three months, typically triggered by the company submitting a Major Amendment (significant new data) late in the review cycle. Stock impact: usually -5-15% on uncertainty, but not catastrophic.

Historical PDUFA Approval Rates

Understanding baseline approval rates helps calibrate your expectations for upcoming PDUFA decisions:

• Overall NDA/BLA approval rate: 85-90% for drugs that reach the filing stage. This is the cumulative success rate — most attrition happens in earlier clinical trial phases.
• Priority Review approval rate: ~90-95%. The granting of Priority Review is itself a positive signal.
• First-in-class drugs: Slightly lower approval rates (~80-85%) because novel mechanisms have less regulatory precedent, but approvals often come with broader labels and faster market uptake.
• Supplemental NDAs (sNDAs): Very high approval rates (~92-95%) because the drug is already approved for another indication and safety data is established.
• Advisory committee positive vote: When an AdCom recommends approval, the FDA follows the recommendation approximately 75-80% of the time.

Key PDUFA Themes for 2026

Oncology Dominance

Oncology continues to dominate the FDA pipeline, representing approximately 35-40% of all PDUFA decisions in 2026. The trend toward targeted therapies, checkpoint inhibitors, ADCs (antibody-drug conjugates), and bispecific antibodies continues to accelerate. For investors, oncology PDUFA dates often offer favorable risk/reward because the approval rates are high and the commercial markets are large.

Cell and Gene Therapy Expansion

2026 features several cell and gene therapy PDUFA dates for indications beyond the initial rare disease approvals. These decisions will shape the commercial viability of the entire sector. Manufacturing capacity, pricing negotiations with payers, and real-world evidence from earlier approvals all factor into the investment thesis.

GLP-1 and Metabolic Disease

The GLP-1 revolution (weight loss and metabolic disease) continues with new formulations, indications, and competitors seeking approval throughout 2026. This category has enormous commercial potential, and PDUFA decisions here move not just the applicant's stock but the entire obesity/metabolic sector.

Rare Disease (Orphan Drug)

Orphan drug designations, which provide market exclusivity and tax credits for drugs treating rare diseases, continue to be a major driver of biotech valuations. Several Orphan Drug PDUFA dates in 2026 involve drugs for conditions with no existing treatment, making approval likely but commercial potential highly variable.

Trading Strategies Around PDUFA Dates

The Pre-PDUFA Run-Up

Biotech stocks with upcoming PDUFA dates often rally in the weeks leading up to the decision as investors position for potential approval. The typical pattern: the stock begins moving 4-6 weeks before the PDUFA date, with acceleration in the final 2 weeks. This run-up creates an opportunity for early positioning, but also risk — you may be buying at inflated levels if the run has already happened.

Strategy: Enter positions 6-8 weeks before the PDUFA date when run-up buying hasn't fully started. Use BiotechSigns to identify upcoming PDUFA dates well in advance and set calendar alerts for optimal entry windows.

The Sell-The-News

Even on approval, some stocks decline — the classic "buy the rumor, sell the news" pattern. This happens when the approval is widely expected and fully priced in, or when the approval comes with restrictions (narrower label than expected, REMS requirements, post-marketing studies). Consider trimming into PDUFA dates rather than holding entire positions through the binary event.

The CRL Recovery

Not all CRLs are fatal. Many involve addressable issues — manufacturing fixes, additional analyses of existing data, or labeling changes that don't require new clinical trials. Stocks that drop 50-60% on a CRL may recover a significant portion over the following months if the company demonstrates a clear path to resubmission. Research the specific CRL issues before bottom-fishing.

Portfolio Exposure Management

If you hold multiple biotech stocks with PDUFA dates in the same month, your portfolio has concentrated binary risk. Consider staggering entries and exits to avoid having multiple simultaneous catalyst bets. Track all upcoming catalysts for your holdings on the BiotechSigns Calendar to manage aggregate risk.

Dilution Risk Around PDUFA Dates

PDUFA dates create a unique dilution dynamic. Companies often time capital raises strategically around FDA decisions:

• Pre-PDUFA offerings: Companies may raise capital before a PDUFA date to fund commercial launch preparations. If the stock has run up on approval anticipation, this creates favorable pricing for the offering. Watch for S-3 filings and ATM agreements in the weeks before a PDUFA date.
• Post-approval offerings: Immediately after approval, companies often raise capital to fund commercialization. The stock is elevated on approval euphoria, creating an optimal window for a capital raise. This is common and generally well-received by the market if the offering is reasonably sized.
• Post-CRL offerings: After a CRL-driven crash, companies may need to raise capital at depressed prices to fund the response to the FDA's deficiency letter. This is the most destructive form of biotech dilution — selling shares at the worst possible time.

Monitor dilution risk alongside catalyst dates using DilutionWatch. The combination of catalyst tracking and dilution surveillance is essential for biotech investors. For a deeper dive, see our Biotech Investing Guide.

Q3 2026 PDUFA Calendar: What to Watch July–September

With H1 2026 complete, investor attention is now shifting to the Q3 2026 FDA decision window — historically one of the busiest periods of the year for PDUFA decisions as the agency works through applications accepted in Q4 2025 and Q1 2026. Here are the key themes and therapy areas that will dominate the July–September 2026 PDUFA calendar:

July 2026: Oncology ADCs and Targeted Therapies

July typically brings a wave of oncology decisions, and 2026 is no exception. Antibody-drug conjugates (ADCs) continue to be the hottest category in cancer therapy — multiple ADCs targeting HER2, TROP2, and novel tumor antigens are expected to receive PDUFA decisions in July. The FDA's recent track record with ADCs has been strong; the combination of targeted delivery and cytotoxic payload has translated well from Phase 3 trials to real-world outcomes. Investors should also watch for supplemental BLA decisions expanding checkpoint inhibitor labels into earlier-line settings.

What to track: PD-L1 inhibitor label expansions (non-small cell lung cancer, gastric, and cervical), KRAS G12C inhibitor second-generation candidates, and new combination regimens for treatment-resistant hematological malignancies. Check the live BiotechSigns PDUFA Calendar for the full July list with approval probability scores.

August 2026: Metabolic Disease and CNS

August 2026 features a concentration of metabolic disease and central nervous system (CNS) PDUFA decisions. The GLP-1/GIP dual agonist space is expanding beyond the established players — several next-generation oral and injectable formulations are in the FDA review pipeline, with some targeting cardiometabolic outcomes beyond weight loss. These decisions carry significant market impact because positive outcomes can shift the competitive landscape in a sector that already commands hundreds of billions in peak sales estimates.

The CNS pipeline for August includes several Alzheimer's disease adjunctive therapies and multiple sleep/neurological disorder candidates. The FDA's evolving standards for neurodegenerative disease endpoints — particularly the shift toward biomarker-based primary endpoints — continue to create both opportunity and regulatory uncertainty.

What to track: Oral GLP-1 receptor agonists with Type 2 diabetes and obesity indications, tau-targeting therapies for early Alzheimer's, and next-generation ADHD formulations with abuse-deterrent features. The metabolic disease decisions in August are particularly high-stakes for sector ETFs (XBI, IBB, LABD).

September 2026: Gene Therapy and Rare Disease

September 2026 is shaping up to be a pivotal month for gene therapy with several landmark PDUFA dates expected for one-time treatments targeting rare monogenic diseases. Unlike earlier gene therapy decisions that focused narrowly on ultra-rare conditions, September's pipeline includes indications with patient populations in the tens of thousands — meaning commercial viability is a genuine question, not a given.

For rare disease decisions, focus on:

• Manufacturing scalability: Gene therapies require complex viral vector manufacturing. FDA inspections of manufacturing facilities are a common CRL trigger — check whether each company has received a Complete Response or pre-approval inspection notice.
• Pricing and reimbursement setup: With gene therapies pricing at $2-4M per treatment, payer contracts need to be in place before launch. Companies with reimbursement agreements already signed are lower execution risk post-approval.
• Long-term durability data: The FDA is increasingly scrutinizing long-term follow-up data for gene therapies, given that some early approvals have shown durability concerns at 3-5 years. Candidates with longer follow-up in their application packages are at lower risk of a CRL on durability grounds.

Q3 2026 Macro Context: FDA Under Scrutiny

The regulatory environment in Q3 2026 carries additional uncertainty compared to prior years. Discussions around FDA review standards, approval timelines, and the role of accelerated approval pathways have intensified in Washington. Investors should factor in a slightly wider range of outcomes — not just approval vs. CRL, but also label scope and any REMS conditions that could limit commercial uptake.

Historically, political pressure on the FDA has had limited direct impact on individual drug decisions, which remain science-driven. However, broader advisory committee activity, surrogate endpoint scrutiny, and changes to the accelerated approval framework can affect entire categories (oncology, CNS, metabolic disease) simultaneously.

How to Screen Q3 2026 PDUFA Setups

With dozens of PDUFA decisions in Q3, not every one represents a compelling trade setup. Use these screens to prioritize:

• Market cap vs. drug commercial potential: A $500M company with a blockbuster-potential drug ($2B+ peak sales) in a high-approval-rate category (oncology, metabolic) is the prototypical setup. Avoid situations where the stock is already pricing in 70%+ of the upside before the decision.
• Clean regulatory history: Has the company received an information request, Complete Response, or advisory committee recommendation in the review cycle? A clean review history significantly increases probability of on-time approval.
• BiotechSigns catalyst score: The BiotechSigns scoring algorithm weights approval probability, commercial market size, competitive position, and dilution risk into a single catalyst score. Focus on high-scoring setups with low dilution risk first.
• Options implied volatility: High IV going into PDUFA dates can make long equity strategies unfavorable — the expected move is already priced into the options. In that case, look at defined-risk strategies or pre-PDUFA entries before the IV spike.

Frequently Asked Questions

What is a PDUFA date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's statutory deadline to make a decision on a drug application. The FDA must respond by this date — either approving the drug, issuing a Complete Response Letter (CRL) requesting more information, or extending the review period. PDUFA dates are the most important catalyst events in biotech investing.

How far in advance are PDUFA dates announced?

PDUFA dates are typically announced when the FDA accepts the NDA (New Drug Application) or BLA (Biologics License Application) for review, which happens 60 days after submission. Standard review PDUFA dates are set 10 months after acceptance; Priority Review dates are set 6 months after acceptance. So investors usually know the PDUFA date 4-8 months before the decision.

Can the FDA make a decision before the PDUFA date?

Yes. The PDUFA date is a deadline, not a scheduled announcement. The FDA can approve a drug weeks or even months before the PDUFA date, and this happens regularly — especially for Priority Review designations and Breakthrough Therapy drugs where the FDA is actively engaged with the sponsor throughout development.

What happens when the FDA misses a PDUFA date?

The FDA occasionally misses PDUFA deadlines, usually by days or weeks rather than months. This typically happens when additional data is requested late in the review cycle or when advisory committee meetings need to be scheduled. While the deadline is statutory, there are no direct penalties for the FDA missing it.

Where can I find a complete PDUFA calendar?

BiotechSigns at biotechsign.com/app/calendar maintains a comprehensive, regularly updated PDUFA calendar covering all upcoming FDA decision dates. The calendar includes scoring for each catalyst based on approval probability, competitive landscape, and market impact potential.

What are the biggest PDUFA dates in Q3 2026?

Q3 2026 (July–September) features a concentrated wave of FDA decisions in oncology ADCs, next-generation GLP-1 metabolic therapies, CNS/Alzheimer treatments, and gene therapy for rare diseases. The exact decision dates shift as extensions are filed and early decisions occur. The BiotechSigns PDUFA Calendar (biotechsign.com/app/calendar) is the most current source for Q3 2026 FDA decision dates with approval probability scores.

How does the FDA regulatory environment affect Q3 2026 PDUFA decisions?

Q3 2026 carries slightly wider outcome uncertainty due to ongoing policy discussions around FDA review standards and accelerated approval pathways. Individual drug decisions remain science-driven, but investors should watch for broader category impacts on oncology accelerated approvals, surrogate endpoint standards, and CNS drug evaluation criteria that could affect multiple PDUFA outcomes simultaneously.